http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15387805

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Research Support, Non-U.S. Gov't
endingPage 1105
issn 0344-5704
1432-0843
issueIdentifier 4
pageRange 1099-1105
publicationName Cancer Chemotherapy and Pharmacology
startingPage 1099
bibliographicCitation Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2011 Dec 06;69(4):1099–105. doi: 10.1007/s00280-011-1788-4.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5399b968d4cde7dd4fead209a08a1bff
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1a852309833996901a51df044e498ee
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cd01df69396198470c5e3be592d1e0cd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2859c5c111db013810e238d0e9177b24
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d154c1991efdb8c16dc00705b1a647b8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f125e48c2b5718a5b85bdfd603c35c2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0c3c721fb53e151c3ab6ce590d9d066
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6558-2246
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_131b90381b66a7310fc5b4295874e128
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_92881679cf35cef9a4fade3018198f08
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86781d0465a4719c847e9598d9dfbe90
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7126-3153
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7953a6b07cef8571be2fca0b0848515d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4abdec9b7b6dd4fc199c6939342d9703
date 2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/22143378
https://pubmed.ncbi.nlm.nih.gov/PMC3313018
https://doi.org/10.1007/s00280-011-1788-4
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664
https://portal.issn.org/resource/ISSN/1432-0843
https://portal.issn.org/resource/ISSN/0344-5704
language English
source https://www.crossref.org/
https://scigraph.springernature.com/
https://pubmed.ncbi.nlm.nih.gov/
title Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
discusses http://id.nlm.nih.gov/mesh/M0469193
http://id.nlm.nih.gov/mesh/M0457532
http://id.nlm.nih.gov/mesh/M0504248
http://id.nlm.nih.gov/mesh/M0543256
http://id.nlm.nih.gov/mesh/M0029863
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8989
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10050
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11520894
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9683
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9415
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9309
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7942
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9149
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d0bb789479d34dbc0811f92fc2bc5049

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID242749350
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID245160169
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID244328266
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248184126
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127638306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128132375
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248766214
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660

Total number of triples: 65.